Founded in 2014 by Dr. Jeff Qi — a professor at Shanghai Jiao Tong University and former Process Development Scientist at Bayer USA — Asia Cell and Gene Therapeutics Group (aCGT) is a pioneering biotechnology company committed to advancing cell and gene therapies for a broad range of challenging diseases.
Our therapeutic platforms harness the power of umbilical cord- derived mesenchymal stem cells (UC-MSCs), induced pluripotent stem cells (iPSCs), and natural killer (NK) cells, among others. With or without additional genetic engineering, our product candidates have demonstrated potent efficacy against treatment-resistant conditions, including ankylosing spondylitis, liver cirrhosis, acute
respiratory distress syndrome (ARDS), and various cancers.
Over the years, aCGT has cultivated a robust, vertically integrated R&D organization spanning discovery research, CMC (Chemistry, Manufacturing, and Controls), and clinical development. This deep expertise has enabled us to build a rich pipeline: in addition to multiple UC-MSC assets nearing IND submission, we have secured five IND approvals for UC-MSC products currently advancing through clinical trials. Concurrently, we are accelerating our iPSC-based programs, with one IND already granted for an iPSC-derived neural progenitor cell (NPC) therapy targeting stroke.
To support our clinical and commercial ambitions, aCGT operates PIC/S-GMP-compliant CRO/CDMO facilities in Hong Kong and the United States for the manufacture of clinical-grade cell products. Furthermore, through long-term strategic partnerships, we have access to two additional cGMP manufacturing sites spanning 4,000 m² and 6,000 m², respectively, significantly expanding our production capacity.
Beyond internal development, aCGT is deeply committed to fostering open innovation by integrating intellectual resources and research outcomes from academic institutions, universities, and industry partners. To this end, we have established a collaborative network that brings together leading laboratories and research organizations, accelerating the translation of innovative cellular therapies and delivering meaningful benefits to patients and society at large.
Looking ahead, aCGT is preparing for its next major milestone: aplanned initial public offering on the Nasdaq Stock Market in the third quarter of 2026. This strategic move will not only provide access to global capital markets to fuel our continued growth and pipeline expansion, but also enhance our visibility and credibility as a leading player in the cell and gene therapy space, reinforcing our commitment to delivering life-changing therapies to patients worldwide.